DUBLIN, March 6, 2018 /PRNewswire/ --

The "Drug analysis: Allergan" drug pipelines has been added to ResearchAndMarkets.com's offering.

Allergan's prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016-2026 is explored.

Snapshot

• Overview - Allergan will finish 2017 positively with pharmaceutical revenues of $15.7bn, up 8% from FY2016, although generic pressures loom in 2018.
• Mid-term outlook - Botox and the successful launch of Vraylar are driving Allergan's pharmaceutical revenue growth, together adding over $2.4bn in sales out to 2021.
• Long-term outlook - Topline revenue will climb to reach around $20bn by 2025, driven by the growth of Botox, as well as the CNS and gastroenterology portfolios.
• Pipeline - Allergan has focused its resources on six star R&D programs that, if successful, will drive long-term growth.
• Events - A Refuse to File letter has been issued for Vraylar for the treatment of PNS, as Esmya is filed for approval for use in uterine fibroids.

Highlights

• Allergan has divested its generics and Anda businesses to its shift focus to branded pharmaceuticals.
• Allergan's CNS portfolio will expand due to the growth of new drugs to treat neurological disorders.
• Allergan's genitourinary portfolio will grow by $181m out to 2026, carried by sales of the oral contraception franchise Lo Loestrin Fe and the launch of pipeline candidate Esmya.
• During 2016-26, the gastroenterology portfolio will grow at a 10.2% CAGR, driven by best-in-class Linzess and Viberzi in IBS.

Model Updates

• Kybella sales downgraded.
• Vraylar supplementary approval treating PNS delayed.
• Restasis generic competition brought forward to Q4 2018.
• Revised Rhofade sales.

Key Topics Covered:

1. Executive Summary

2. Q2 2017 Review

• Increased R&D investment
• Pipeline update
• Recent launches
• Growth outlook
• Bold intellectual property protection

3. Q3 2017 Review

• Allergan reports solid quarter as generic pressures loom in 2018

4. Company Context

• Acquisition trail
• Growth Pharma
• Pfizer terminated plans for Allergan combination
• Allergan's transformation to branded growth pharma
• 2017 outlook: acquisitions and R&D spending
• Allergan's SWOT analysis
• Allergan's key events and catalysts

5. Facts and Figures

• Allergan's prescription pharma sales outlook
• Allergan's therapy area dynamics
• Allergan's regional pharma sales outlook
• Allergan's top 10 products over 2016-26
• Allergan's growth drivers and resistors
• Allergan's launch/core/expiry analysis
• Allergan's financial outlook
• Allergan's M&A history

6. Therapy Area Analysis

• Botox will provide sustained growth across both therapeutic and cosmetic indications
• Additional therapeutic indications are not included in the forecast
• Central nervous system
• Genitourinary
• Gastroenterology

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mjzf9v/allergan_drug?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

View original content:http://www.prnewswire.com/news-releases/allergan-drug-analysis--outlook-2016-2026---generic-pressures-loom-in-2018-300608971.html

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com